In a filing, Kiniksa Pharmaceuticals International Plc revealed its CHIEF OPERATING OFFICER Tessari Eben unloaded Company’s shares for reported $0.27 million on Feb 10 ’25. In the deal valued at $19.57 per share,14,000 shares were sold. As a result of this transaction, Tessari Eben now holds 81,975 shares worth roughly $1.62 million.
Then, Tessari Eben bought 14,000 shares, generating $274,041 in total proceeds.
Before that, Tessari Eben sold 14,000 shares. Kiniksa Pharmaceuticals International Plc shares valued at $255,413 were divested by the CHIEF OPERATING OFFICER at a price of $18.24 per share. As a result of the transaction, Tessari Eben now holds 88,975 shares, worth roughly $1.75 million.
Jefferies initiated its Kiniksa Pharmaceuticals International Plc [KNSA] rating to a Buy in a research note published on September 13, 2024; the price target was $40. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early May with a ‘”an Overweight”‘ rating. BofA Securities also remained covering KNSA and reiterated its “Buy” recommendation on June 29, 2020. BofA/Merrill started covering the stock on April 01, 2020. It rated KNSA as “a Buy”.
Price Performance Review of KNSA
On Tuesday, Kiniksa Pharmaceuticals International Plc [NASDAQ:KNSA] saw its stock jump 0.46% to $19.72. Over the last five days, the stock has gained 0.87%. Kiniksa Pharmaceuticals International Plc shares have fallen nearly -0.30% since the year began. While a 52-week high of $28.15 was reached on 01/28/25, a 52-week low of $16.56 was recorded on 01/13/25. SMA at 50 days reached $19.76, while 200 days put it at $22.07.
Levels Of Support And Resistance For KNSA Stock
The 24-hour chart illustrates a support level at 19.23, which if violated will result in even more drops to 18.74. On the upside, there is a resistance level at 20.18. A further resistance level may holdings at 20.64. The Relative Strength Index (RSI) on the 14-day chart is 49.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 38.70%. Stochastics %K at 63.98% indicates the stock is a holding.
The most recent change occurred on March 11, 2019 when Barclays began covering the stock and recommended ‘”an Overweight”‘ rating along with a $26 price target.
